Investigational Drug Information for Acebilustat
✉ Email this page to a colleague
What is the drug development status for Acebilustat?
Acebilustat is an investigational drug.
There have been 4 clinical trials for Acebilustat.
The most recent clinical trial was a Phase 1 trial, which was initiated on February 2nd 2022.
The most common disease conditions in clinical trials are COVID-19, Lymphedema, and [disabled in preview]. The leading clinical trial sponsors are Stanford University, Quotient Sciences, and Celtaxsys, Inc.
There are three US patents protecting this investigational drug and fifty-five international patents.
Summary for Acebilustat
| US Patents | 3 |
| International Patents | 55 |
| US Patent Applications | 39 |
| WIPO Patent Applications | 14 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2022-02-02) |
| Vendors | 34 |
Recent Clinical Trials for Acebilustat
| Title | Sponsor | Phase |
|---|---|---|
| Trial of Acebilustat for the Treatment of Upper Arm Lymphedema | Celltaxis LLC | Phase 2 |
| Trial of Acebilustat for the Treatment of Upper Arm Lymphedema | Stanford University | Phase 2 |
| COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol | Stanford University | Phase 2 |
Clinical Trial Summary for Acebilustat
Top disease conditions for Acebilustat
Top clinical trial sponsors for Acebilustat
US Patents for Acebilustat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Acebilustat | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| Acebilustat | ⤷ Try a Trial | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | Celtaxsys, Inc. (Atlanta, GA) | ⤷ Try a Trial |
| Acebilustat | ⤷ Try a Trial | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents | NeRRe Therapeutics Limited (Herts, GB) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Acebilustat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Acebilustat | Australia | AU2017261372 | 2036-05-05 | ⤷ Try a Trial |
| Acebilustat | Canada | CA3023278 | 2036-05-05 | ⤷ Try a Trial |
| Acebilustat | China | CN107847398 | 2036-05-05 | ⤷ Try a Trial |
| Acebilustat | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
